DOI: 10.1097/pg9.0000000000000356 ISSN:
Clinical Remission of Severe Crohn’s Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b
Lauren V. Collen, Peter E. Newburger, Scott B. Snapper- General Earth and Planetary Sciences
- General Environmental Science
Glycogen storage disease type 1b (GSD1b) is associated with inflammatory bowel disease and congenital neutropenia. Neutropenia in GSD1b is caused by the accumulation of 1,5-anhydroglucitol-6-phosphate. Empagliflozin is an antidiabetic drug that promotes renal excretion of this metabolite. We report on a patient with refractory GSD1b-associated inflammatory bowel disease who is in clinical remission on empagliflozin monotherapy.